Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 542

1.

Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.

Kawakami E, Tabata J, Yanaihara N, Ishikawa T, Koseki K, Iida Y, Saito M, Komazaki H, Shapiro JS, Goto C, Akiyama Y, Saito R, Saito M, Takano H, Yamada K, Okamoto A.

Clin Cancer Res. 2019 May 15;25(10):3006-3015. doi: 10.1158/1078-0432.CCR-18-3378. Epub 2019 Apr 11.

PMID:
30979733
2.

Development and evaluation of a cervical cancer screening system in Cambodia: A collaborative project of the Cambodian Society of Gynecology and Obstetrics and Japan Society of Obstetrics and Gynecology.

Ueda Y, Kawana K, Yanaihara N, Banno K, Chhit M, Uy K, Kruy L, Sann CS, Ishioka-Kanda M, Akaba H, Matsumoto Y, Fujita N, Yano T, Koum K, Okamoto A, Kimura T.

J Obstet Gynaecol Res. 2019 Apr 11. doi: 10.1111/jog.13968. [Epub ahead of print]

PMID:
30977232
3.

Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.

Takenaka M, Köbel M, Garsed DW, Fereday S, Pandey A, Etemadmoghadam D, Hendley J, Kawabata A, Noguchi D, Yanaihara N, Takahashi H, Kiyokawa T, Ikegami M, Takano H, Isonishi S, Ochiai K, Traficante N, Gadipally S, Semple T, Vassiliadis D, Amarasinghe K, Li J, Mir Arnau G, Okamoto A, Friedlander M, Bowtell DDL; Australian Ovarian Cancer Study Group.

Clin Cancer Res. 2019 Apr 9. doi: 10.1158/1078-0432.CCR-18-3691. [Epub ahead of print]

PMID:
30967419
4.

PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma.

Morikawa A, Hayashi T, Shimizu N, Kobayashi M, Taniue K, Takahashi A, Tachibana K, Saito M, Kawabata A, Iida Y, Ueda K, Saito M, Yanaihara N, Tanabe H, Yamada K, Takano H, Nureki O, Okamoto A, Akiyama T.

Oncotarget. 2018 Feb 22;9(20):15266-15274. doi: 10.18632/oncotarget.24555. eCollection 2018 Mar 16.

5.

Dedifferentiated endometrial carcinoma: A report of three cases and review of the literature.

Yokomizo R, Yamada K, Iida Y, Kiyokawa T, Ueda K, Saito M, Yanaihara N, Nakamura M, Okamoto A.

Mol Clin Oncol. 2017 Dec;7(6):1008-1012. doi: 10.3892/mco.2017.1437. Epub 2017 Oct 3.

6.

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.

Bookman MA, Okamoto A, Stuart G, Yanaihara N, Aoki D, Bacon M, Fujiwara K, González-Martín A, Harter P, Kim JW, Ledermann J, Pujade-Lauraine E, Quinn M, Ochiai K; 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii30-viii35. doi: 10.1093/annonc/mdx449. Review.

7.

Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.

Kawabata A, Yanaihara N, Nagata C, Saito M, Noguchi D, Takenaka M, Iida Y, Takano H, Yamada K, Iwamoto M, Kiyokawa T, Okamoto A.

Gynecol Oncol. 2017 Sep;146(3):609-614. doi: 10.1016/j.ygyno.2017.06.027. Epub 2017 Jun 30.

PMID:
28673661
8.

Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.

Jang JYA, Yanaihara N, Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, Ledermann J, Shimada M, Kiyokawa T, Kim BG, Matsumura N, Kaku T, Kuroda T, Nagayoshi Y, Kawabata A, Iida Y, Kim JW, Quinn M, Okamoto A.

J Gynecol Oncol. 2017 Jul;28(4):e54. doi: 10.3802/jgo.2017.28.e54. Review.

9.

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP.

Nat Genet. 2017 Jun;49(6):856-865. doi: 10.1038/ng.3849. Epub 2017 Apr 24.

PMID:
28436987
10.

Polypoid endometriosis of the ovary and müllerianosis of pelvic lymph nodes mimicking an ovarian carcinoma with lymph node metastasis.

Iida Y, Tabata J, Yorozu T, Kitai S, Ueda K, Saito M, Yanaihara N, Yamada K, Okamoto A.

Int Cancer Conf J. 2017 Apr 20;6(4):145-148. doi: 10.1007/s13691-017-0295-9. eCollection 2017 Oct.

11.

Feasibility of reduced port surgery applying Higuchi's transverse incision.

Ueda K, Nagayoshi Y, Kawabata A, Kuroda T, Iida Y, Saitou M, Yanaihara N, Sugimoto K, Sakamoto M, Okamoto A.

Gynecol Minim Invasive Ther. 2017 Jan-Mar;6(1):12-16. doi: 10.1016/j.gmit.2016.05.003. Epub 2016 Jun 15.

12.

MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma.

Yanaihara N, Noguchi Y, Saito M, Takenaka M, Takakura S, Yamada K, Okamoto A.

PLoS One. 2016 Sep 9;11(9):e0162584. doi: 10.1371/journal.pone.0162584. eCollection 2016.

13.

Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy.

Nagata C, Tanabe H, Takakura S, Narui C, Saito M, Yanaihara N, Okamoto A.

J Obstet Gynaecol Res. 2015 Sep;41(9):1440-8. doi: 10.1111/jog.12740. Epub 2015 Jun 26.

PMID:
26111609
14.

Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.

Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K, Okamoto A.

Mol Carcinog. 2016 May;55(5):832-41. doi: 10.1002/mc.22325. Epub 2015 Apr 9.

PMID:
25856562
15.

Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.

Takenaka M, Saito M, Iwakawa R, Yanaihara N, Saito M, Kato M, Ichikawa H, Shibata T, Yokota J, Okamoto A, Kohno T.

Int J Oncol. 2015;46(6):2389-98. doi: 10.3892/ijo.2015.2951. Epub 2015 Apr 3.

PMID:
25846456
16.

DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.

Yamaguchi N, Mimoto R, Yanaihara N, Imawari Y, Hirooka S, Okamoto A, Yoshida K.

Tumour Biol. 2015 Aug;36(8):5913-23. doi: 10.1007/s13277-015-3264-y. Epub 2015 Feb 25.

PMID:
25712377
17.

Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.

Okamoto A, Sehouli J, Yanaihara N, Hirata Y, Braicu I, Kim BG, Takakura S, Saito M, Yanagida S, Takenaka M, Yamaguchi N, Morikawa A, Tanabe H, Yamada K, Yoshihara K, Enomoto T, Itamochi H, Kigawa J, Matsumura N, Konishi I, Aida S, Aoki Y, Ishii N, Ochiai K, Akiyama T, Urashima M.

PLoS One. 2015 Feb 6;10(2):e0116977. doi: 10.1371/journal.pone.0116977. eCollection 2015.

18.

MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.

Hirata Y, Murai N, Yanaihara N, Saito M, Saito M, Urashima M, Murakami Y, Matsufuji S, Okamoto A.

BMC Cancer. 2014 Nov 3;14:799. doi: 10.1186/1471-2407-14-799.

19.

Salmonella ovarian abscess in a patient with rheumatoid arthritis (RA): a case report with literature review.

Inoue M, Yanaihara N, Okamoto A.

Clin Exp Obstet Gynecol. 2014;41(4):465-7. Review.

PMID:
25134301
20.

Uterine endometrial carcinoma with trophoblastic differentiation: a case report with literature review.

Seki T, Yanaihara N, Hirata Y, Fukunaga M, Tanaka T, Okamoto A.

Eur J Gynaecol Oncol. 2014;35(4):461-4. Review.

PMID:
25118494
21.

Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.

Suzuki K, Takakura S, Saito M, Morikawa A, Suzuki J, Takahashi K, Nagata C, Yanaihara N, Tanabe H, Okamoto A.

Int J Gynecol Cancer. 2014 Sep;24(7):1181-9. doi: 10.1097/IGC.0000000000000178.

PMID:
25010038
22.

MicroRNA Involvement in Human Cancers.

Yanaihara N, Harris CC.

Clin Chem. 2013 Dec;59(12):1811-2. doi: 10.1373/clinchem.2012.198176. Epub 2013 Mar 5. No abstract available.

23.

The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels.

Koyama-Nasu R, Takahashi R, Yanagida S, Nasu-Nishimura Y, Oyama M, Kozuka-Hata H, Haruta R, Manabe E, Hoshino-Okubo A, Omi H, Yanaihara N, Okamoto A, Tanaka T, Akiyama T.

PLoS One. 2013;8(1):e53710. doi: 10.1371/journal.pone.0053710. Epub 2013 Jan 10.

24.

[The general rules for clinical and pathological management of trophoblastic diseases--2011, the 3rd edition].

Tanaka T, Yanagida S, Yanaihara N.

Nihon Rinsho. 2012 Jun;70 Suppl 4:695-8. Japanese. No abstract available.

PMID:
23156334
25.

[Treatment overview of ovarian cancer].

Yanaihara N, Ochiai K.

Nihon Rinsho. 2012 Jun;70 Suppl 4:557-9. Japanese. No abstract available.

PMID:
23156309
26.

[Molecular genetic of ovarian cancer].

Yanaihara N, Okamoto A, Ochiai K, Tanaka T.

Nihon Rinsho. 2012 Jun;70 Suppl 4:475-9. Japanese. No abstract available.

PMID:
23156293
27.

Cytokine gene expression signature in ovarian clear cell carcinoma.

Yanaihara N, Anglesio MS, Ochiai K, Hirata Y, Saito M, Nagata C, Iida Y, Takakura S, Yamada K, Tanaka T, Okamoto A.

Int J Oncol. 2012 Sep;41(3):1094-100. doi: 10.3892/ijo.2012.1533. Epub 2012 Jun 26.

PMID:
22751940
28.

Molecular genetic analysis of nongestational choriocarcinoma in a postmenopausal woman: a case report and literature review.

Hirata Y, Yanaihara N, Yanagida S, Fukui K, Iwadate K, Kiyokawa T, Tanaka T.

Int J Gynecol Pathol. 2012 Jul;31(4):364-8. doi: 10.1097/PGP.0b013e318241d556.

PMID:
22653351
29.

Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy.

Kunito S, Takakura S, Nagata C, Saito M, Yanaihara N, Yamada K, Okamoto A, Sasaki H, Ochiai K, Tanaka T.

J Obstet Gynaecol Res. 2012 Dec;38(12):1367-75. doi: 10.1111/j.1447-0756.2012.01884.x. Epub 2012 May 28.

PMID:
22639843
30.

Pilot study of CD147 protein expression in epithelial ovarian cancer using monoclonal antibody 12C3.

Ueda K, Yamada K, Kiyokawa T, Iida Y, Nagata C, Hamada T, Saito M, Aoki K, Yanaihara N, Takakura S, Okamoto A, Ochiai K, Ohkawa K, Tanaka T.

J Obstet Gynaecol Res. 2012 Sep;38(9):1211-9. doi: 10.1111/j.1447-0756.2012.01853.x. Epub 2012 May 8.

PMID:
22563698
31.

Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma.

Iida Y, Aoki K, Asakura T, Ueda K, Yanaihara N, Takakura S, Yamada K, Okamoto A, Tanaka T, Ohkawa K.

Int J Oncol. 2012 Jun;40(6):2122-30. doi: 10.3892/ijo.2012.1406. Epub 2012 Mar 19.

PMID:
22447231
32.

Cyclin D1 predicts the prognosis of advanced serous ovarian cancer.

Hashimoto T, Yanaihara N, Okamoto A, Nikaido T, Saito M, Takakura S, Yasuda M, Sasaki H, Ochiai K, Tanaka T.

Exp Ther Med. 2011 Mar;2(2):213-219. Epub 2011 Jan 18.

33.

[Molecular genetic of gynecological cancer].

Yanaihara N, Okamoto A, Yanagida S, Ochiai K, Tanaka T.

Nihon Rinsho. 2010 Aug;68 Suppl 8:489-93. Review. Japanese. No abstract available.

PMID:
20976924
34.

Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.

Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Smyth GK, Campbell IG, Bowtell DD; Australian Ovarian Cancer Study.

PLoS One. 2010 Sep 10;5(9). pii: e11408. doi: 10.1371/journal.pone.0011408.

35.

Vitamin D receptor polymorphisms and prognosis of patients with epithelial ovarian cancer.

Tamez S, Norizoe C, Ochiai K, Takahashi D, Shimojima A, Tsutsumi Y, Yanaihara N, Tanaka T, Okamoto A, Urashima M.

Br J Cancer. 2009 Dec 15;101(12):1957-60. doi: 10.1038/sj.bjc.6605414. Epub 2009 Nov 10.

36.

MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.

Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC.

Clin Cancer Res. 2009 Oct 1;15(19):6192-200. doi: 10.1158/1078-0432.CCR-09-1467. Epub 2009 Sep 29.

37.

ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression.

Kumamoto K, Fujita K, Kurotani R, Saito M, Unoki M, Hagiwara N, Shiga H, Bowman ED, Yanaihara N, Okamura S, Nagashima M, Miyamoto K, Takenoshita S, Yokota J, Harris CC.

Int J Cancer. 2009 Sep 15;125(6):1306-15. doi: 10.1002/ijc.24437.

38.

Mesenchymal to epithelial transition in the human ovarian surface epithelium focusing on inclusion cysts.

Okamoto S, Okamoto A, Nikaido T, Saito M, Takao M, Yanaihara N, Takakura S, Ochiai K, Tanaka T.

Oncol Rep. 2009 May;21(5):1209-14.

PMID:
19360296
39.

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC.

JAMA. 2008 Jan 30;299(4):425-36. doi: 10.1001/jama.299.4.425.

40.

Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.

Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW, Harris CC.

J Natl Cancer Inst. 2007 Aug 15;99(16):1257-69. Epub 2007 Aug 8.

PMID:
17686824
41.

Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC.

Cancer Cell. 2006 Mar;9(3):189-98.

42.

A microRNA expression signature of human solid tumors defines cancer gene targets.

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61. Epub 2006 Feb 3.

43.

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.

Clin Cancer Res. 2005 Aug 15;11(16):6030-9.

44.

FGF7-like gene is associated with pericentric inversion of chromosome 9, and FGF7 is involved in the development of ovarian cancer.

Yasuhara T, Okamoto A, Kitagawa T, Nikaido T, Yoshimura T, Yanaihara N, Takakura S, Tanaka T, Ochiai K, Ohtake Y.

Int J Oncol. 2005 May;26(5):1209-16.

PMID:
15809711
45.

BLM helicase facilitates Mus81 endonuclease activity in human cells.

Zhang R, Sengupta S, Yang Q, Linke SP, Yanaihara N, Bradsher J, Blais V, McGowan CH, Harris CC.

Cancer Res. 2005 Apr 1;65(7):2526-31.

46.

Genes associated with the genesis of leiomyoma of the uterus in a commonly deleted chromosomal region at 7q22.

Saito E, Okamoto A, Saito M, Shinozaki H, Takakura S, Yanaihara N, Ochiai K, Tanaka T.

Oncol Rep. 2005 Mar;13(3):469-72.

PMID:
15706419
47.

Intracisternal galanin/angiotensin II interactions in central cardiovascular control.

Díaz-Cabiale Z, Parrado C, Vela C, Coveñas R, Yanaihara N, Fuxe K, González-Barón S, Narváez JA.

Regul Pept. 2005 Apr 15;127(1-3):133-40.

PMID:
15680479
48.

[Overview of key genes implicated in ovarian carcinogenesis].

Yamada K, Ueda K, Yanaihara N, Motegi M, Okamoto A, Ochiai K, Tanaka T.

Nihon Rinsho. 2004 Oct;62 Suppl 10:454-7. Review. Japanese. No abstract available.

PMID:
15535286
49.

[Molecular genetics of ovarian cancer].

Yanaihara N, Okamoto A, Takakura S, Yamada K, Ochiai K, Tanaka T.

Nihon Rinsho. 2004 Oct;62 Suppl 10:441-8. Review. Japanese. No abstract available.

PMID:
15535284
50.

Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer.

Yanaihara N, Nishioka M, Kohno T, Otsuka A, Okamoto A, Ochiai K, Tanaka T, Yokota J.

Int J Cancer. 2004 Oct 20;112(1):150-4.

Supplemental Content

Loading ...
Support Center